8-K: Shuttle Pharmaceuticals Secures $2 Million Revolving Loan to Fuel Growth Initiatives

Shuttle Pharmaceuticals Holdings, Inc. has entered into a Revolving Loan Agreement for up to $2 million to support general corporate purposes, including a potential public equity offering.

Summary

• Shuttle Pharmaceuticals Holdings, Inc. secured a Revolving Loan Agreement with a lender on February 28, 2025, for a principal amount of up to $2,000,000.
• The company can draw upon the loan at its discretion for general corporate purposes, including financing a Qualified Public Equity Offering.
• WestPark Capital, Inc. acted as the financial advisor and received a $20,000 fee upon signing the agreement, with an additional 4% fee for each draw down.
• The Revolving Note bears an interest rate of 18% per annum, calculated on a 360-day year basis, accruing daily from the date of each draw down.
• The entire Payment Amount is due on the first anniversary of the Closing Date.
• As a condition of closing, four members of the Board of Directors resigned, and three nominees designated by the Lender were appointed to the Board.
• The company will use its reasonable best efforts to consummate an underwritten public offering of not more than $6,000,000 of its common stock and/or any convertible security or warrant.
• The Revolving Loan Agreement contains negative covenants that restrict the company from repurchasing more than a de minimis number of shares of its common stock.

Sentiment

Score: 6

Explanation: The announcement is neutral. Securing a loan provides financial resources, but the high interest rate and board changes introduce some concerns. The potential public offering is a positive sign for future growth.

Positives

• The $2 million revolving loan provides Shuttle Pharmaceuticals with additional financial flexibility.
• The funds can be used for general corporate purposes, including financing a potential public equity offering.
• The company is actively pursuing a public equity offering of up to $6 million, which could provide further capital.

Negatives

• The 18% annual interest rate on the loan is relatively high.
• The company is restricted from repurchasing more than a de minimis number of shares of its common stock.
• Four members of the Board of Directors resigned as a condition of the loan.

Risks

• The company's ability to repay the loan depends on its future financial performance.
• The company may not be successful in completing a public equity offering.
• The negative covenants in the loan agreement could restrict the company's ability to operate its business.

Future Outlook

Shuttle Pharmaceuticals intends to use the proceeds from the loan for general corporate purposes and to finance a potential public equity offering of up to $6 million. The company will use its reasonable best efforts to consummate a Qualified Public Equity Offering as soon as practicable.

Industry Context

This announcement reflects a common strategy for small pharmaceutical companies to secure funding for research and development and clinical trials. Revolving loans provide flexibility, while the pursuit of a public equity offering indicates a desire for longer-term capital.

Comparison to Industry Standards

• The 18% interest rate is high compared to standard bank loans but is not uncommon for smaller companies or bridge financing.
• Comparable companies often use a mix of debt and equity financing to fund operations and growth.
• The size of the potential public equity offering ($6 million) is relatively small, suggesting the company is at an early stage of development.

Management Changes

Stakeholder Impact

• Shareholders may be impacted by the potential public equity offering, which could dilute existing ownership.
• Employees may benefit from the additional funding, which could support continued operations and growth.
• The company's creditors are impacted by the new debt obligation.

Next Steps

• The company will draw upon the loan as needed for general corporate purposes.
• The company will work to consummate a Qualified Public Equity Offering.
• A determination as to which of the new independent directors will serve on the Audit Committee, Nomination and Corporate Governance Committee, and Compensation Committee will be made in the coming days.

Key Dates